Form 4: Humacyte Director Charles Bruce Green Acquires 50,000 Stock Options
SEC Form 4 Filing
Director Charles Bruce Green reports acquisition of 50,000 Humacyte stock options on June 13, 2024.
Summary
- Charles Bruce Green, a director of Humacyte, Inc., reported the acquisition of 50,000 stock options on June 13, 2024.
- The options have an exercise price of $7.20.
- The options become exercisable starting June 13, 2025, with 25% vesting initially, followed by monthly vesting of 1/48 of the option until June 13, 2028.
- The expiration date for the options is June 13, 2034.
- Following the transaction, Green directly owns 50,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- The transaction provides insight into director compensation and alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: Acquisition of 50,000 stock options. |
| 06/13/2025 | First 25% of the option becomes exercisable. |
| 06/13/2028 | End of monthly vesting period for the options. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.